CINECA IRIS Institutional Research Information System

ROSSO, Chiara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.618
AS - Asia 11.769
EU - Europa 9.364
SA - Sud America 507
AF - Africa 332
OC - Oceania 249
Continente sconosciuto - Info sul continente non disponibili 15
Totale 34.854
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.795
CN - Cina 7.434
IT - Italia 1.904
DE - Germania 1.411
SE - Svezia 929
JP - Giappone 768
FR - Francia 764
GB - Regno Unito 697
IE - Irlanda 677
IN - India 513
KR - Corea 511
CA - Canada 504
SG - Singapore 447
HK - Hong Kong 424
TR - Turchia 358
ES - Italia 353
UA - Ucraina 319
TW - Taiwan 317
NL - Olanda 302
VN - Vietnam 297
PL - Polonia 289
MX - Messico 283
BR - Brasile 270
FI - Finlandia 262
AT - Austria 258
AU - Australia 232
RU - Federazione Russa 207
EG - Egitto 192
DK - Danimarca 168
GR - Grecia 164
BE - Belgio 158
IR - Iran 117
ID - Indonesia 116
RO - Romania 105
CZ - Repubblica Ceca 80
CH - Svizzera 78
IL - Israele 74
PT - Portogallo 74
PK - Pakistan 62
PE - Perù 57
CO - Colombia 56
SA - Arabia Saudita 52
TH - Thailandia 49
CL - Cile 44
AR - Argentina 41
IQ - Iraq 36
MY - Malesia 34
NO - Norvegia 31
HU - Ungheria 29
EC - Ecuador 28
PH - Filippine 27
LT - Lituania 17
DZ - Algeria 16
UZ - Uzbekistan 16
LB - Libano 15
MO - Macao, regione amministrativa speciale della Cina 15
BG - Bulgaria 14
CM - Camerun 14
EU - Europa 14
GH - Ghana 14
AE - Emirati Arabi Uniti 13
NG - Nigeria 13
NZ - Nuova Zelanda 13
SK - Slovacchia (Repubblica Slovacca) 13
MA - Marocco 12
SI - Slovenia 12
ZA - Sudafrica 12
JO - Giordania 11
RS - Serbia 11
BD - Bangladesh 9
BF - Burkina Faso 9
BY - Bielorussia 9
HR - Croazia 9
CY - Cipro 8
ET - Etiopia 8
PS - Palestinian Territory 8
GT - Guatemala 7
LY - Libia 7
VE - Venezuela 7
CU - Cuba 6
CV - Capo Verde 6
MN - Mongolia 6
PA - Panama 6
GE - Georgia 5
PR - Porto Rico 5
EE - Estonia 4
KH - Cambogia 4
KZ - Kazakistan 4
MZ - Mozambico 4
SN - Senegal 4
CI - Costa d'Avorio 3
GU - Guam 3
LV - Lettonia 3
MD - Moldavia 3
QA - Qatar 3
SY - Repubblica araba siriana 3
TD - Ciad 3
TN - Tunisia 3
YE - Yemen 3
AL - Albania 2
Totale 34.806
Salva come PNG Salva come JPEG
Città #
Chandler 1.283
Beijing 1.246
Ann Arbor 986
Fairfield 760
Dublin 666
Shanghai 631
Ashburn 557
Houston 480
Redwood City 469
Guangzhou 448
Woodbridge 385
Wilmington 367
Dearborn 348
Torino 323
Nanjing 299
Seattle 289
Singapore 281
Hangzhou 264
Villeurbanne 256
Jacksonville 251
Nyköping 239
Cambridge 231
Ottawa 231
Pisa 224
Wuhan 211
Vienna 204
Medford 200
Princeton 194
Tokyo 194
Taipei 185
Chengdu 181
Dong Ket 172
Jinan 165
New York 141
Seoul 139
Rome 130
Warsaw 130
Central 124
Fremont 123
Turin 121
Zhengzhou 120
Changsha 117
Boston 114
Chongqing 113
Hefei 109
London 108
Los Angeles 99
Shenyang 99
San Diego 92
Changchun 83
Milan 79
Tianjin 79
Istanbul 76
Nanning 74
Munich 73
Toronto 73
Central District 72
Brussels 69
Sydney 69
Kunming 66
Delhi 65
Boardman 62
Fuzhou 62
Hebei 61
Hong Kong 61
Helsinki 57
Nanchang 54
Washington 54
Cairo 52
Paris 51
Frankfurt am Main 50
Madrid 49
Athens 48
Xian 48
Norwalk 47
Berlin 46
Qingdao 45
Copenhagen 43
Harbin 43
San Mateo 43
Suzhou 42
Hanoi 40
Xi'an 40
Santiago 39
Amsterdam 38
Barcelona 38
Ankara 37
Duncan 36
Newcastle upon Tyne 36
Phoenix 35
San Jose 35
Chicago 34
Lima 34
Mumbai 34
Pittsburgh 34
Stockholm 34
Bengaluru 33
São Paulo 33
Jakarta 31
Mexico 31
Totale 17.667
Salva come PNG Salva come JPEG
Nome #
Liver cancer: Connections with obesity, fatty liver, and cirrhosis 7.112
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis 3.013
Serum zonulin in patients with inflammatory bowel disease: a pilot study 1.720
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 1.292
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease 942
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance 906
Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease 676
Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein. 638
Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. 563
Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study 505
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 498
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 457
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes 432
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 352
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 304
Endocrine manifestations of chronic HCV infection 284
Fecal calprotectin: beyond intestinal organic diseases 284
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. 259
Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease 251
Physiopathology of intestinal barrier and the role of zonulin 205
Liver fibrosis: the 2017 state of art 202
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease 198
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 192
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease 189
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 185
The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease 184
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 174
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 168
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load 167
How to diagnose NAFLD in 2016 165
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 160
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 158
Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation 158
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 157
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 153
Metabolic Syndrome and Severity of Fibrosis in Nonalcoholic Fatty Liver Disease: An Age-Dependent Risk Profiling Study 153
Non-alcoholic fatty liver disease and extra-hepatic cancers 153
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 149
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 147
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 145
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 145
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 141
Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic acid breath test 141
Diagnosis of Helicobacter pylori infection: a look into molecular aspects of urea breath test 138
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 132
Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C 127
Increased epicardial fat and early signs of impaired diastolic and systolic left ventricular function in non-diabetic, non-dyslipidemic, normotensive patients with Nonalcoholic Fatty Liver Disease 127
Angiopoietin like protein 4 (ANGPTL4): a marker of alteration in lipid metabolism, insulin resistance and ectopic fat accumulation 127
Metabolic handling of an oral fat load in NAFLD patients. 126
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 125
Risk factors for metabolic syndrome after liver transplantation: what has changed over time 125
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 124
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 123
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 123
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis 123
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease 122
In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease 122
Association Between Gut Permeability and Insulin Resistance: Any Role for Zonulin in Patients with Non-Alcoholic Fatty Liver Disease? 121
Insulin resistance and liver damage are associated with early signs of left ventricular systolic dysfunction in patients with Non Alcoholic Fatty Liver Disease independent of diabetes, hypertension and dyslipidemia 120
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD. 117
Basic and clinical aspects of resistin 116
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 115
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 115
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 114
Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 113
Adverse impact of visceral fat on lipid and metabolic profile in fatty liver disease 113
Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma 112
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 109
The combination of Index of NASH score and liver stiffness improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with NonAlcoholic Fatty Liver Disease. 108
IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients 107
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 104
Altered metabolic profile and adipocyte insulin resistance mark severe liver fibrosis in patients with chronic liver disease 104
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 104
Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma 104
Serum cytokeratin-19 fragments (CYFRA 21-1) for the prediction of overall survival in patients with hepatocellular carcinoma 104
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease 104
Bile acids composition modulate insulin resistance in non-diabetic patients with NAFLD 103
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 103
Biomarkers of oncogenesis, adipose tissue dysfunction and systemic inflammation for the detection of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 103
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 101
The clinical role of serum epidermal growth factor receptor 3 in hepatitis c virus-infected patients with early hepatocellular carcinoma 101
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 99
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C 99
Adipose tissue insulin resistance and inflammation, but not reduced hepatic fat oxidation, are associated to active NASH and severe fibrosis. 99
Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) 98
Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology 96
Alteration in lipid metabolism after an oral fat load in patients with NAFLD. 95
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 95
Prevalence of patients with non-alcoholic fatty liver disease: from primary care to tertiary centers. The Turin experience 95
PNPLA3 gene variants and insulin resistance in patients with genotype-1 chronic hepatitis C 94
Hepatocellular carcinoma and metabolic risk factors in a main reference center in Italy 94
Serum free fatty acid composition is associated with different degrees of fibrosis. 94
Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology 94
Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis 93
Moving towards core antigen for the management of patients with overt and occult HBV infection 93
Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression in patients with NAFLD 92
After oral fat load NAFLD subjects and healthy controls show different serum free fatty acid trends. 90
Analytical and clinical comparison between two different chemiluminescent enzyme immunoassays for the measurement of C-peptide in serum 90
Angiopoietin-like4 is associated with lipid metabolism and severe fibrosis in non-diabetic patients with non-alcoholic fatty liver disease 89
Increased Pre-Hepatic Insulin Levels Are Directly Related to Nash, Fibrogenesis and Fibrosis in Non Diabetic NAFLD Patients but Not in Type 2 Diabetes 88
Totale 30.643
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.665
article - articoli 0
book - libri 0
conference - conferenze 22.012
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.677
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.898 0 233 211 433 322 521 400 331 416 444 294 293
2020/20215.413 342 439 365 380 545 442 456 355 524 505 457 603
2021/20226.055 312 353 406 522 494 420 599 556 630 471 767 525
2022/20236.351 534 483 305 515 535 1.021 562 455 654 357 427 503
2023/20246.746 617 689 638 620 651 679 465 672 178 456 520 561
2024/2025766 485 281 0 0 0 0 0 0 0 0 0 0
Totale 35.794